HAMBURG, Germany, Oct 9, 2023 – 3B Scientific, a manufacturer and marketer of medical simulation products and anatomical models for healthcare education, announces its acquisition of Wallcur LLC, a prominent provider of healthcare simulation products. This acquisition broadens 3B Scientific’s product offering and further demonstrates our ongoing commitment to advancing medical training.

Wallcur, a respected name in healthcare simulation for over 40 years, has earned a reputation for its innovative and high-quality simulated medicine products that enhance medical education across the globe. Wallcur’s mission is to provide ideas and products that both stimulate and simulate clinical learning in a safe non-clinical environment to help graduate the most competent, confident, and ready practitioner for today’s healthcare system. By joining forces with Wallcur, 3B Scientific aims to further empower healthcare professionals and educators with cutting-edge training solutions.

The synergies between 3B Scientific and Wallcur are evident in their shared dedication to improving patient outcomes through effective training. This strategic alliance will combine the strengths of both companies, enabling them to provide an even broader range of simulation solutions that cater to the evolving needs of medical educators and practitioners.

“This acquisition is a reflection of our unwavering commitment to enhancing healthcare education worldwide,” said Todd A. Murray, CEO of 3B Scientific. “Wallcur’s expertise and track record in healthcare simulation perfectly align with our mission. Together, we will continue to deliver world-class training solutions that have a lasting impact on medical education.”

Wallcur’s managing member, Brett Lanuti, expressed enthusiasm about the merger, sharing, “Joining forces with 3B Scientific is an exciting opportunity to take our simulation offerings to new heights. We are confident that this partnership will benefit the healthcare community by raising the bar for medical education.” Concurrent with the transaction Mr. Lanuti will transition out of the business and Wendy LaGrange currently Vice President of Sales and Business Development will assume a leadership role for Wallcur as Vice President and Managing Director for the Wallcur business.

As part of the acquisition, Wallcur will continue to operate under its brand name, and its headquarters will remain in San Diego, CA. Customers can expect the same level of excellence and commitment to quality that Wallcur has consistently delivered over the years.

About the 3B Scientific Group

3B Scientific, established in 1948 in Hamburg, Germany, is a global provider of state-of-the-art medical simulators, catering to medical education training across all levels. Building on an extensive range of top-quality educational and simulation products, the 3B Scientific Group of Companies has established a strong presence in over 120 countries worldwide. Using this wide-reaching platform, 3B Scientific continues to drive its mission forward: advancing the delivery of medical and healthcare education worldwide.

For further insights into 3B Scientific, visit www.3bscientific.com.

About Wallcur LLC

Wallcur is a trusted name in healthcare simulation, specializing in products that enhance medical education and training. With a history of excellence dating back to 40 years, Wallcur has been at the forefront of developing realistic and effective simulation solutions that benefit medical professionals and students worldwide.

Wallcur was born out of a desire to teach future nurses using an innovative approach to learning. Wallcur started with the world-renowned MATH FOR MEDS book, which became the highly successful standard for learning dosages and solutions throughout the US and Canada. Today, with continued educator feedback, collaborative research, and design, Wallcur has upheld its mission to provide the most up-to-date, realistic, and cost-effective simulated clinical practice available.

To learn more about Wallcur, visit www.3bscientific.com/wallcur.

^{Role of Virtual Twins in Accelerating Medical Research, Delivering Personalized Care}

VELIZY-VILLACOUBLAY, France, Sep 21, 2023 – Dassault Systèmes introduced ‘Emma Twin,’ an avatar designed to raise awareness of the key role that virtual twins have in advancing healthcare and the innovations that are shaping the future of medicine.

Through a rich social media program, Emma Twin will share stories explaining how the virtual twin of her body was created from anonymous health data to be used for an infinite number of tests that give doctors and researchers a profound understanding of diseases and the effects of new and improved treatments.

Her social media posts will document her participation in ongoing research and medical innovations including:  clinical trials using Medidata solutions; the reaction of her heart to different procedures in the Living Heart project; testing CorNeat Vision’s corneal transplants; epilepsy and Alzheimer’s disease studies in the Living Brain project; wearing the IASO drug administration and monitoring device; and optimizing the home for older adults.  They will also highlight: DAMAE Medical’s portable microscope for detecting skin cancer; Dynocardia’s blood pressure monitoring solution; FEops’ cardiac monitoring; LUCID Implants’ customized facial implants; and the VORTHEx radiotherapy simulation experience.

“Through Emma Twin, we will share stories about the impact of virtual twins on healthcare, in an engaging, meaningful way,” said Victoire de Margerie, vice president, corporate equity, marketing & communications, Dassault Systèmes.  “Our virtual twins have been used to swiftly develop COVID-19 vaccines, optimize surgical procedures, and provide patients with a greater understanding of treatment options.  By leveraging our pioneering technology, we can draw attention to major healthcare challenges and demonstrate how the virtual world improves outcomes in real life.”

For 40 years, Dassault Systèmes’ virtual twins – data-enriched, evolving 3D models that replicate reality with scientific accuracy and are used to test and improve performance virtually – have catalyzed sustainable innovations that improve quality of life for consumers, citizens and patients.

Virtual twins accelerate the development of solutions to urgent needs for more precise, preventive healthcare by enabling research and health-related disciplines to model, test and treat a human body as precisely, safely and effectively as other industries can with cars, buildings or airplanes.

Emma Twin is the next act in Dassault Systèmes’ “The Only Progress is Human” initiative, dedicated to healthcare and patient experience.  In 2020, the company launched The Only Progress is Human to increase awareness of societal and environmental challenges and inspire the use of virtual worlds to drive sustainable innovations in areas such as urbanization and water conservation.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE company, is a catalyst for human progress. They provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries.

For more information, visit www.3ds.com.

NEW YORK, NY, Sep 21, 2023 –  Medidata, a Dassault Systèmes company, announced the launch of the Medidata Diversity Program, the industry’s most comprehensive solution for improving diversity, equity, and inclusion in clinical trials.

The Medidata Diversity Program supports biopharmaceutical and medical device companies and clinical research organizations (CROs) by addressing common systemic and clinical barriers that can hinder a diverse range of individuals from participating in clinical trials. By combining capabilities across Medidata AI and Medidata Patient Cloud portfolios, the program creates a novel and unique approach to achieving diversity throughout the clinical trial process by improving awareness and experiences for patients, streamlining access to trials, enabling decentralization, and supporting data-driven decision-making needed to execute the modern diversity action plans required for regulatory success.

This landmark launch coincides with increasing dialogue among industry leaders and regulators about the need for greater diversity throughout the clinical trial process. Historically, clinical trials have recruited predominantly Caucasian participants, rather than being representative of the patient populations most affected by the disease. These blind spots can lead to a lack of understanding about how treatments may affect different populations and create inequitable access to treatments that complicate data accuracy and the path to future clinical development.

The U.S. Food and Drug Administration (FDA) indicated that achieving greater diversity in clinical trials will be a key focus for regulators to help evaluate new treatments and methods – especially in therapeutic areas that are known to disproportionately impact diverse communities. The FDA’s latest Draft Guidance on Diversity Plans aims to improve enrollment of underrepresented populations in clinical trials by encouraging investigators and sponsors to create a framework to define and meet specific diversity goals.

“Facilitating more diverse participation in clinical trials is a critical and complex challenge, not only for the life sciences industry but for the patients and caregivers participating in the trials,” said Anthony Costello, chief executive officer, Patient Cloud, Medidata. “The Medidata Diversity Program, the most comprehensive solution to date, will help sponsors and CROs move from awareness about a diversity challenge to planning and solving for it as a standard and sustainable part of their clinical development programs.”

The Diversity Program comprises a suite of innovative and industry-leading solutions including Medidata AI Intelligent Trials, myMedidata Registries and eConsent, the Medidata Patient Insights Program, and Medidata’s partnership with Circuit Clinical – a national network of sites focused on diverse patient populations with localized investigators, trained on Medidata decentralized clinical trial technology. Designed to embed diversity into every aspect of the process, this program positions Medidata as a catalyst for cultivating diversity, closing disparities, and achieving true clinical trial success.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,700+ customers and partners access the world’s most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company, is headquartered in New York City and has offices around the world to meet the needs of its customers.

Discover more at www.medidata.com.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE company, is a catalyst for human progress. They provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries.

For more information, visit www.3ds.com.